187752-49-4 Usage
Uses
Used in Pharmaceutical Industry:
(R,S)3,5-dimethoxymandelic acid is used as an intermediate for the synthesis of various drugs, contributing to the development of new medications and therapies.
Used in Chiral Synthesis:
(R,S)3,5-dimethoxymandelic acid is used as a chiral resolving agent, which is essential for the separation and production of enantiomerically pure compounds, a critical aspect in the pharmaceutical industry due to the different biological activities of enantiomers.
Used in Antifungal Applications:
(R,S)3,5-dimethoxymandelic acid has been studied for its potential antifungal properties, making it a candidate for the development of new antifungal agents to combat fungal infections.
Used in Antibacterial Applications:
(R,S)3,5-dimethoxymandelic acid has also been investigated for its potential antibacterial properties, which could lead to the creation of new antibacterial drugs to address bacterial resistance and infections.
Check Digit Verification of cas no
The CAS Registry Mumber 187752-49-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,7,7,5 and 2 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 187752-49:
(8*1)+(7*8)+(6*7)+(5*7)+(4*5)+(3*2)+(2*4)+(1*9)=184
184 % 10 = 4
So 187752-49-4 is a valid CAS Registry Number.
187752-49-4Relevant academic research and scientific papers
Mutasynthesis of Glycopeptide Antibiotics: Variations of Vancomycin's AB-Ring Amino Acid 3,5-Dihydroxyphenylglycine
Weist, Stefan,Kittel, Claudia,Bischoff, Daniel,Bister, Bojan,Pfeifer, Volker,Nicholson, Graeme J.,Wohlleben, Wolfgang,Suessmuth, Roderich D.
, p. 5942 - 5943 (2007/10/03)
In the mutasynthetic approach, the ΔdpgA mutant of the vancomycin-type glycopeptide antibiotic producer Amycolatopsis balhimycina, which is deficient in the synthesis of 3,5-dihydroxyphenylglycine (DPg), was supplemented with synthetic DPg analogues to obtain the corresponding modified glycopeptides. Sterically more demanding 3,5-disubstituted methoxy derivatives as well as monosubstituted DPg analogues were accepted as substrates. These facts indicate that steric and electronic requirements suffice in several cases for the oxidative closure of the AB ring, thus leading to the generation of novel antibiotically active glycopeptide derivatives. The results represent a further step in evaluating the potential of mutasynthesis for peptidic secondary metabolites. Copyright
